CSL Limited
CSL
Rank in Stocks
#361
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Share Price
$138.93
Market Cap
$66.67B
Change (1 day)
0.97%
Change (1 year)
-2.04%
Country
AU
Trade CSL Limited (CSL)
Category
Healthcare
Earnings for CSL Limited (CSL)
Earnings in Jun 2026 TTM: $-4.02B
According to CSL Limited latest financial reports the company's current earnings are $-4.02B. In 2024 the company made an earning of $3.38B, an increase over its 2023 earnings that were of $2.66B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for CSL Limited from 2000 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-4.02B | -207.85% |
| 2025 | $3.72B | 10.34% |
| 2024 | $3.38B | 26.74% |
| 2023 | $2.66B | -4.19% |
| 2022 | $2.78B | -6.80% |
| 2021 | $2.98B | 15.92% |
| 2020 | $2.57B | 9.89% |
| 2019 | $2.34B | 2.63% |
| 2018 | $2.28B | 35.00% |
| 2017 | $1.69B | 8.61% |
| 2016 | $1.56B | -9.22% |
| 2015 | $1.71B | 6.84% |
| 2014 | $1.60B | 19.64% |
| 2013 | $1.34B | 5.36% |
| 2012 | $1.27B | -7.31% |
| 2011 | $1.37B | 38.29% |
| 2010 | $992.87M | 11.00% |
| 2009 | $894.45M | 2.37% |
| 2008 | $873.74M | 56.73% |
| 2007 | $557.47M | 493.43% |
| 2006 | $93.94M | -74.77% |
| 2005 | $372.39M | 201.20% |
| 2004 | $123.64M | 168.99% |
| 2003 | $45.96M | -7.38% |
| 2002 | $49.63M | -8.38% |
| 2001 | $54.17M | 88.04% |
| 2000 | $28.81M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -231.34% |
US
|
|
| $-3.09B | -23.14% |
US
|
|
| - | - |
CH
|
|
| $1.95B | -148.57% |
NL
|
|
| $3.01B | -174.84% |
BE
|
